Catalog No.: PC-43229Not For Human Use, Lab Use Only.
MCC950 (CP456773, CRID3) sodium is a potent, selective, small-molecule inhibitor of NLRP3 inflammasome with IC50 of 7.5 and 8.1 nM in BMDM and HMDM, respectively.
MCC950 (CP456773, CRID3) sodium is a potent, selective, small-molecule inhibitor of NLRP3 inflammasome with IC50 of 7.5 and 8.1 nM in BMDM and HMDM, respectively.
MCC950 (CP-456773) specifically inhibits activation of NLRP3, does not inhibit NLRC4, AIM2, TLR signalling or priming of NLRP3.
MCC950 (CP-456773) blocks NLRP3 induced ASC oligomerization, does not block K+ efflux, Ca2+ flux or NLRP3-ASC interactions.
MCC950 (CP-456773) reduces interleukin-1β (IL-1β) production in vivo and attenuates the severity of experimental autoimmune encephalomyelitis (EAE), rescues neonatal lethality in mouse model of CAPS and is active in ex vivo samples from individuals with Muckle-Wells syndrome.
Physicochemical Properties
M.Wt
426.4618
Formula
C20H23N2NaO5S
Appearance
Solid
CAS No.
Storage
Solide Powder
-20 °C 12 Months; 4°C 6 Months
In Solvent
-80 °C 6 Months; -20°C 6 Months
Shipping
Solubility
H2O: ≥ 30 mg/mL
Chemical Name/SMILES
2-Furansulfonamide, N-[[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)amino]carbonyl]-4-(1-hydroxy-1-methylethyl)-, sodium salt (1:1)
References
1. Coll RC, et al. Nat Med. 2015 Mar;21(3):248-55.
2. Krishnan SM, et al. Br J Pharmacol. 2016 Feb;173(4):752-65.
3. Baker PJ, et al. Eur J Immunol. 2015 Oct;45(10):2918-26.
4. Primiano MJ, et al. J Immunol. 2016 Sep 15;197(6):2421-33.
